Jacob Patton Hickman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jacob Patton Hickman has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Aatman Pushkarkumar Vasoya
Department of Computer Science, Indiana University Bloomington, 700 N Woodlawn Avenue, Bloomington, IN 47408, USA
1 shared publication - Md Hasan Imam Shihab
Department of Computer Science, Indiana University Bloomington, Bloomington, IN 47408, USA
1 shared publication - Menghao Huang
Department of Biochemistry, Molecular Biology & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
1 shared publication - Sachin Anil Ghag
Department of Biochemistry, Molecular Biology & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
1 shared publication - Vinamrata Sharma
Department of Computer Science, Indiana University Bloomington, 700 N Woodlawn Avenue, Bloomington, IN 47408, USA
1 shared publication - Xiaoqing Huang
Indiana University, School of Medicine, Carmel, IN USA
1 shared publication
Latest Publications
- Open Access
From Proteomic Signatures to Candidate Endotypes in Obesity, Type 2 Diabetes, MASLD/MASH, and MetALD: Study Designs, Bioinformatics, and Biostatistical Strategies
Obesity, type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and dual-etiology metabolic dysfunction-associated alcohol-related liver disease (MetALD) form an overlapping metabolic dysfunction spectrum, rather than a single linear disease sequence. Proteomics offers a functional readout of this spectrum by measuring proteins, proteoforms, and protein species involved in tissue injury, inflammation, metabolic stress, and inter-organ communication. This review asks how proteomic data can support mechanism-based stratification, rather than simply generate disease-associated signatures. We summarize advances in circulating and tissue-based proteomics across obesity, T2D, MASLD/MASH, and MetALD, highlighting shared and disease-specific pathways such as mitochondrial dysfunction, extracellular matrix remodeling, immune activation, proteostasis stress, and endocrine crosstalk. We emphasize that proteomic clusters should be considered candidate endotypes only when they are reproducible, mechanistically coherent, linked to tissue or causal evidence, and clinically informative. We also evaluate bioinformatics and biostatistical strategies needed for reliable interpretation, including preprocessing, missing-data handling, normalization, longitudinal modeling, multi-omics integration, protein quantitative trait locus (pQTL) analysis, colocalization, and Mendelian randomization. Finally, we discuss how proteoforms, post-translational modifications (PTMs), and platform-dependent proteome complexity shape interpretation. Together, these concepts provide practical guidance for moving from proteomic signatures to candidate endotypes and for prioritizing clinically useful biomarkers and therapeutic targets.
Open AccessFrom Proteomic Signatures to Candidate Endotypes in Obesity, Type 2 Diabetes, MASLD/MASH, and MetALD: Study Designs, Bioinformatics, and Biostatistical Strategies
Obesity, type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and dual-etiology metabolic dysfunction-associated alcohol-related liver disease (MetALD) form an overlapping metabolic dysfunction spectrum, rather than a single linear disease sequence. Proteomics offers a functional readout of this spectrum by measuring proteins, proteoforms, and protein species involved in tissue injury, inflammation, metabolic stress, and inter-organ communication. This review asks how proteomic data can support mechanism-based stratification, rather than simply generate disease-associated signatures. We summarize advances in circulating and tissue-based proteomics across obesity, T2D, MASLD/MASH, and MetALD, highlighting shared and disease-specific pathways such as mitochondrial dysfunction, extracellular matrix remodeling, immune activation, proteostasis stress, and endocrine crosstalk. We emphasize that proteomic clusters should be considered candidate endotypes only when they are reproducible, mechanistically coherent, linked to tissue or causal evidence, and clinically informative. We also evaluate bioinformatics and biostatistical strategies needed for reliable interpretation, including preprocessing, missing-data handling, normalization, longitudinal modeling, multi-omics integration, protein quantitative trait locus (pQTL) analysis, colocalization, and Mendelian randomization. Finally, we discuss how proteoforms, post-translational modifications (PTMs), and platform-dependent proteome complexity shape interpretation. Together, these concepts provide practical guidance for moving from proteomic signatures to candidate endotypes and for prioritizing clinically useful biomarkers and therapeutic targets.